Search | Clinical Trials Finder

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Chronic Sinusitis
Interventions: dupilumab, placebo; Biological · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more

Conditions: Asthma
Interventions: Dupilumab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nasal Polyps
Interventions: Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more

Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 12,343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Innovaderm Research Inc.; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Mullica Hill, New Jersey

Conditions: Healthy
Interventions: SAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more

Conditions: Peanut Allergy
Interventions: Dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Mountain View, California • Tampa, Florida • Indianapolis, Indiana + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more

Conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], Placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Dermatitis
Interventions: REGN668; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • Riverside, California • Miami, Florida + 7 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Alopecia Areata
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Eosinophilic Oesophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Atopic Dermatitis
Interventions: tralokinumab; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Pruritus
Interventions: Dupilumab, Placebo, Fexofenadine (loratadine if not available); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 16 more

Conditions: Asthma
Interventions: Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more

Search by objective public record fields.

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Molecular Signatures of Cutaneous Dupilumab Response

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Tralokinumab for Dupilumab Failures

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma